Dimensional Fund Advisors LP raised its stake in Alkermes Plc (NASDAQ:ALKS) by 4.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 191,640 shares of the company’s stock after buying an additional 7,797 shares during the period. Dimensional Fund Advisors LP owned approximately 0.13% of Alkermes Plc worth $10,651,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ALKS. Scout Investments Inc. acquired a new position in Alkermes Plc during the third quarter valued at $14,117,000. D. E. Shaw & Co. Inc. increased its position in Alkermes Plc by 18.8% in the third quarter. D. E. Shaw & Co. Inc. now owns 1,665,836 shares of the company’s stock valued at $78,345,000 after buying an additional 264,019 shares during the last quarter. Baker BROS. Advisors LP acquired a new position in Alkermes Plc during the third quarter valued at $11,769,000. Los Angeles Capital Management & Equity Research Inc. acquired a new position in Alkermes Plc during the third quarter valued at $8,594,000. Finally, Panagora Asset Management Inc. increased its position in Alkermes Plc by 504.2% in the third quarter. Panagora Asset Management Inc. now owns 167,779 shares of the company’s stock valued at $7,891,000 after buying an additional 140,012 shares during the last quarter. Hedge funds and other institutional investors own 95.52% of the company’s stock.
Shares of Alkermes Plc (NASDAQ:ALKS) opened at 56.73 on Friday. The stock has a 50 day moving average of $58.15 and a 200 day moving average of $55.28. The stock’s market cap is $8.65 billion. Alkermes Plc has a one year low of $36.71 and a one year high of $62.50.
Alkermes Plc (NASDAQ:ALKS) last released its quarterly earnings results on Wednesday, February 15th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.11. The business earned $213.50 million during the quarter, compared to the consensus estimate of $206.38 million. Alkermes Plc had a negative return on equity of 12.75% and a negative net margin of 36.92%. The business’s quarterly revenue was up 30.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.14) EPS. On average, analysts forecast that Alkermes Plc will post $0.04 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Dimensional Fund Advisors LP Raises Stake in Alkermes Plc (ALKS)” was posted by Markets Daily and is owned by of Markets Daily. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at https://www.themarketsdaily.com/2017/04/21/dimensional-fund-advisors-lp-raises-stake-in-alkermes-plc-alks.html.
Several research analysts have weighed in on ALKS shares. Cowen and Company restated a “positive” rating and set a $65.00 price objective on shares of Alkermes Plc in a report on Tuesday, March 21st. Cantor Fitzgerald restated a “neutral” rating and set a $51.00 price objective on shares of Alkermes Plc in a report on Thursday, March 16th. Jefferies Group LLC restated a “buy” rating and set a $70.00 price objective on shares of Alkermes Plc in a report on Monday, April 3rd. Finally, TheStreet upgraded shares of Alkermes Plc from a “d+” rating to a “c” rating in a report on Wednesday, February 15th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $63.55.
In other Alkermes Plc news, Director Robert A. Breyer sold 4,000 shares of the business’s stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $60.00, for a total transaction of $240,000.00. Following the completion of the sale, the director now directly owns 7,156 shares in the company, valued at approximately $429,360. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Shane Cooke sold 20,000 shares of the business’s stock in a transaction dated Thursday, March 2nd. The shares were sold at an average price of $60.00, for a total value of $1,200,000.00. Following the sale, the insider now owns 73,068 shares of the company’s stock, valued at $4,384,080. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 110,800 shares of company stock valued at $6,468,781. Corporate insiders own 4.75% of the company’s stock.
Alkermes Plc Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes Plc and related companies with MarketBeat.com's FREE daily email newsletter.